News & Events

ACT Genomics Co. Limited, aleader in precision diagnostics and clinical testing, and mProbe Taiwan Inc., apioneer in proteomics technology for precision health, have signed a Memorandumof Understanding (MOU) to collaborate on advancing precision medicine acrossAsia. The agreement aims to combine the unique expertise of both companies toprovide cutting-edge diagnostic solutions to healthcare providers in theregion.

ACT Genomics (Hong Kong) Limited (“ACTG”) and Cancerinformation have officiallysigned a Memorandum of Understanding (MoU) to enhance cancer patients'understanding of cancer and precision medicine and to emphasize the importanceof related testing. This collaboration is dedicated to advancing patienteducation and increasing the accessibility of precision medicine. 

The MOU establishes the framework for both companies to explore collaborative opportunities that align with the Japanese healthcare system's needs, combining ACT Genomics' expertise in genomic profiling with LSI Medience’s extensive experience in clinical testing. Initially, the collaboration will focus on integrating genomic profiling into clinical research, enhancing the provision of personalized and effective data to Japanese researchers.

この覚書は、日本の医療システムのニーズに合わせた協力機会を両社が探求するための枠組みを設定します。これには、ACT Genomicsのゲノムプロファイリングの専門知識とLSIメディエンスの臨床試験における広範な経験が組み合わされます。当初、この協力は臨床研究にゲノムプロファイリングを統合することに焦点を当て、日本の研究者に提供されるパーソナライズされた効果的なデータの向上を図ります。

Precision medicine is a global development trend, and Taiwan is expected to include NGS (Next-Generation Sequencing) in its health insurance by 2024, enabling more precise cancer treatment and potentially reducing the economic burden on cancer patients.

ACT Genomics statement regarding the false information on the recent acquisition.

New medical technologies have been advancing more rapidly than ever, including the application of precision medicine and artificial intelligence in cancer clinical treatment planning and biomarkers discovery.

One of the causes for non-small cell lung cancer is related to gene mutation. Currently, the known gene mutations that cause lung cancer includes EGFR, ALK, BRAF, ROS1 and METex14, etc.

The next-generation oncology diagnostic powerhouse is formed in Asia, ACT Genomics and Sanomics offering total solutions to patients, medical professionals, pharmaceutical companies, and research institutes globally.

CerbACT Asia (Taipei, Taiwan), a Cerba Research and ACT Genomics joint venture, unveiled its new purpose-built facility to empower precision medicine for better patient outcomes.